Pacira Settles Patent Dispute Over Exparel With Fresenius, Delays Pain Med' Generics Entry Until 2030, Stock Jumps
PCRX settled litigations regarding Exparel patents with multiple pharmaceutical companies. Settlement includes a license for limited generic entry beginning in early 2030. Pacira’s fourth-quarter sales for Exparel increased 3% year-over-year to $147.7 million. Analysts maintain 'Buy' ratings with price targets raised significantly after the news. PCRX stock rose 16.8%, reflecting positive market sentiment on this announcement.
View signal analysis